Welcome to our dedicated page for Mereo Biopharma SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mereo BioPharma Group plc (NASDAQ: MREO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed with the Securities and Exchange Commission. These filings offer primary-source information on Mereo’s financial condition, clinical development updates, and material corporate events.
Mereo’s Form 8-K filings, for example, have furnished press releases covering quarterly financial results, cash and cash equivalents, and recent corporate highlights. They also describe key clinical milestones, such as the progress of the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta, Data Monitoring Committee recommendations to proceed to final analysis, and subsequent top-line results. Other 8-K reports outline developments in the company’s pipeline, including partnering activities and regulatory designations for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease.
Through this page, users can follow how Mereo reports its operating performance, research and development spending, and capital structure over time via its SEC submissions. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, 10-Ks or 10-Qs without reading every line.
Investors interested in MREO can use the filings page to monitor material updates on clinical programs, financing, and corporate agreements as they are reported to the SEC. Real-time access, combined with AI-generated explanations, supports efficient review of Mereo BioPharma’s regulatory history and ongoing disclosure record.
Mereo BioPharma Group plc furnished a corporate update and investor materials, including a press release and a presentation used for the J.P. Morgan Healthcare Conference and other meetings. These materials are provided as exhibits and are not deemed filed under U.S. securities laws.
The company also updated its cash runway guidance. As of December 31, 2025, cash and cash equivalents were approximately
Mereo BioPharma Group plc received a Schedule 13G filing from investment firm 683 Capital and related parties reporting a significant passive stake. As of January 6, 2026, 683 Capital Partners, LP beneficially owned 65,083,815 ordinary shares, represented by 13,016,763 American Depositary Shares (ADS), which equals about 8.18% of the ordinary shares.
The percentage is based on 795,658,504 ordinary shares outstanding as of November 7, 2025. 683 Capital Management, LLC, as investment manager, and Ari Zweiman, as managing member, may each be deemed to share beneficial ownership. The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Mereo BioPharma.
Mereo BioPharma Group plc (MREO) furnished an update under Item 2.02, announcing financial results for the third quarter ended September 30, 2025, and recent corporate highlights. The full details are contained in a press release dated November 10, 2025, furnished as Exhibit 99.1.
The company noted that the information in Item 2.02 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act. MREO’s American Depositary Shares, each representing five ordinary shares, trade on The Nasdaq Stock Market LLC under the symbol MREO.
Frazier Life Sciences entities report passive holdings in Mereo BioPharma (MREO), detailing share counts, ADS equivalents and ownership percentages. The filing shows Frazier Life Sciences Public Fund, L.P. directly holds 32,430,690 Ordinary Shares, represented by 6,486,138 American Depositary Shares, equal to 4.1% of the issuer's 795,001,444 outstanding Ordinary Shares used for the percentage calculation. Additional Frazier entities hold 8,941,155 Ordinary Shares (1.1%, 1,788,231 ADS), 4,065,485 Ordinary Shares (0.5%, 813,097 ADS) and 1,763,230 Ordinary Shares (0.2%, 352,646 ADS). Voting and dispositive power over these holdings is reported as shared, with no sole voting or dispositive power asserted by the listed reporting persons. The statement corrects prior attributions by clarifying that committee members of certain general partners are not attributed beneficial ownership of the shares held by the funds. The filing also includes a certification that the securities were not acquired to influence control of the issuer and disclaims that the reporting persons are necessarily members of a group or beneficial owners beyond what is expressly stated.
Janus Henderson Group plc and an affiliated fund report significant passive holdings in Mereo BioPharma Group plc American Depositary Shares. Janus Henderson Group plc beneficially owns 17,688,592 ADS, equal to 11.1% of the class, with shared voting and shared dispositive power only and no sole voting or dispositive power. An affiliated vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports 15,203,597 ADS (9.6% of the class), also held with shared voting and dispositive power only.
The filing is a Schedule 13G/A disclosure indicating the holdings are reported as held in the ordinary course of business; the reporting persons certify the securities were not acquired to influence control of the issuer. The filing identifies reporting classifications and a power of attorney authorizing signatories to file required ownership reports.
Mereo BioPharma Group plc reported several financing and collaboration items including a £0.265 convertible loan note held by Novartis that was convertible at holder discretion and bore 9% interest with a maturity date of February 10, 2025. The company issued two tranches of Novartis warrants (2,000,000 in 2023 plus a 2020 tranche) exercisable at £0.265 until February 2028; warrants were recognized as equity instruments. The company issued ordinary shares to AstraZeneca as part of an amended license agreement and received an aggregate upfront payment of $5.0 million, plus a $0.5 million milestone paid upon execution, and issued additional shares later. Outstanding warrants equal approximately 0.3% of issued share capital as of June 30, 2025 (0.4% as of December 31, 2024). The filing discloses milestone receipts of $50.0 million under Ultragenyx (setrusumab), $4.0 million under Feng Biosciences (navicixizumab), and $1.0 million under ReproNovo (leflutrozole), plus later milestone payments noted. The company lists a range of development, regulatory, manufacturing, commercialization and intellectual property costs and risks that could affect timing and cash needs.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
